Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10773101 | 0.85 | CA12 (0.40) | MLYCDHTT | |
| SCHEMBL23501821 | 0.84 | GAA (0.59) | ALDH1A1 | |
| SCHEMBL2707534 | 0.84 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL7610482 | 0.84 | TSHR (0.46) | — | |
| SCHEMBL7835897 | 0.83 | BCL2A1 (0.45) | ALDH1A1BCL2A1 | |
| SCHEMBL3349318 | 0.83 | MLYCD (0.41) | MLYCDCXCR2BCL2A1 | |
| SCHEMBL7837974 | 0.83 | MLYCD (0.50) | MLYCDHTT | |
| SCHEMBL14248561 | 0.81 | ACHE (0.44) | MLYCDALDH1A1CXCR2ADORA2AADORA2B | |
| SCHEMBL7618380 | 0.80 | MLYCD (0.40) | MLYCDCXCR2 | |
| SCHEMBL6571962 | 0.80 | KMT2A (0.43) | MLYCDHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3626716-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-03-25 | — | — | EP | disclosed |
| US-9981955-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3309157-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-3002281-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9511056-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2016-12-06 | — | — | US | disclosed |
| EP-3002281-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2016-04-06 | — | — | EP | disclosed |
| US-8841278-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140249074-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2014-09-04 | — | — | US | disclosed |
| US-8822430-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| EP-2430014-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| WO-2010132601-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| EP-0719773-B1 | IMIDAZOLIDINONE DERIVATIVE, ACID-ADDITION SALT THEREOF, AND REMEDY FOR SENILE DEMENTIA | KYORIN SEIYAKU KK (JP) | 2001-11-21 | — | — | EP | disclosed |
| CN-1043990-C | Imidazolidinone derivative, acid-addition salt therefor, and remedy for senile dementia | KYORIN SEIYAKU KK (JP) | 1999-07-07 | — | — | CN | disclosed |
| US-5789425-A | Imidazolidinone derivatives, their acid adducts and therapeutic drugs for senile dementia | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1998-08-04 | — | — | US | disclosed |
| CN-1135215-A | Imidazolidinone derivative, acid-addition salt therefor, and remedy for senile dementia | KYORIN SEIYAKU KK (JP) | 1996-11-06 | — | — | CN | disclosed |
| EP-0719773-A1 | IMIDAZOLIDINONE DERIVATIVE, ACID-ADDITION SALT THEREOF, AND REMEDY FOR SENILE DEMENTIA | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1996-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | MLYCD 1820/4885HTT 1294/4885ALDH1A1 3957/4885 |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | MLYCD 1820/4885HTT 1294/4885ALDH1A1 3957/4885 |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | MLYCD 1820/4885HTT 1294/4885ALDH1A1 3957/4885 |
| US-20140249074-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | MLYCD 1820/4885HTT 1294/4885ALDH1A1 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.